Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: a multi-center retrospective study

被引：0
|
作者：
Shragai, Tamir [1 ]
Magen, Hila [2 ]
Lavi, Noa [3 ]
Gatt, Moshe [4 ]
Trestman, Svetlana [1 ]
Zektser, Miri [5 ]
Ganzel, Chezi [6 ]
Jarchowsky, Osant [7 ]
Berger, Tamar [8 ]
Tadmor, Tamar [9 ]
Leiba, Merav [10 ]
Hertzog-Zarfaty, Katrin [11 ]
Horowitz, Netanel [3 ]
Shapira, Michael [12 ]
Varssano, David [1 ]
Berger, Yoav [2 ]
Frenkel, Shahar [4 ]
Krauthammer, Mark [1 ]
Avivi, Irit [13 ,14 ]
Luttwak, Efrat [1 ]
Cohen, Yael [13 ,14 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Sheba Med Ctr, Ramat Gan, Israel
[3] Rambam Hlth Care Campus, Haifa, Israel
[4] Hadassah Med Ctr, Jerusalem, Israel
[5] Soroka Univ Hosp, Beer Sheva, Israel
[6] Shaare Zedek Med Ctr, Jerusalem, Israel
[7] Meir Med Ctr, Kefar Sava, Israel
[8] Rabin Med Ctr, Petah Tiqwa, Israel
[9] Bnei Zion Med Ctr, Haifa, Israel
[10] Assuta Ashdod Med Ctr, Ashdod, Israel
[11] Shamir Med Ctr, Beer Yaagov, Israel
[12] Assuta Ramat HaChayal Hosp, Tel Aviv, Israel
[13] Tel Aviv Sourasky Ichilov Med Ctr, Tel Aviv, Israel
[14] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-114
引用
收藏
页码：S98 / S98
页数：1
相关论文
共 50 条
  • [21] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
    Condorelli, Annalisa
    Garibaldi, Bruno
    Gagliano, Caterina
    Romano, Alessandra
    Del Fabro, Vittorio
    Parrinello, Nunziatina Laura
    Longo, Antonio
    Cosentino, Sebastiano
    Di Raimondo, Francesco
    Conticello, Concetta
    ACTA HAEMATOLOGICA, 2024, 147 (04) : 493 - 498
  • [22] Belantamab-mafodotin treatment for relapsed or refractory multiple myeloma
    Stocker, Nicolas
    HEMATOLOGIE, 2020, 26 (02): : 99 - 100
  • [23] The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
    Becnel, Melody R.
    Lee, Hans C.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [24] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
    Condorelli, Annalisa
    Garibaldi, Bruno
    Gagliano, Caterina
    Romano, Alessandra
    Del Fabro, Vittorio
    Parrinello, Nunziatina Laura
    Longo, Antonio
    Cosentino, Sebastiano
    Di Raimondo, Francesco
    Conticello, Concetta
    ACTA HAEMATOLOGICA, 2021,
  • [25] Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Roussou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Theodorakakou, Foteini
    Spiliopoulou, Vassiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gavriatopoulou, Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S203 - S204
  • [26] A real-world study of belantamab mafodotin in a heavily pretreated population of multiple myeloma patients
    Bird, Sarah
    Bishop, Ellouise
    Panopoulou, Katerina
    Saso, Radovan
    Mir, Farheen
    Stern, Simon
    Kaiser, Martin
    Boyd, Kevin
    Pawlyn, Charlotte
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 60 - 61
  • [27] Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience
    Lebel, Eyal
    Vainstein, Vladimir
    Milani, Paolo
    Palladini, Giovanni
    Shragai, Tamir
    Lavi, Noa
    Magen, Hila
    Miri, Assayag
    Mazza, Irit Avivi
    Gatt, Moshe E.
    BLOOD, 2023, 142
  • [28] Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
    Adrián Alegre
    Gonzalo Benzo
    Rafael Alonso
    Joaquín Martínez-López
    Ana Jimenez-Ubieto
    Clara Cuéllar
    Elham Askari
    Elena Prieto
    Concepción Aláez
    Beatriz Aguado
    Alberto Velasco
    Isabel Krsnik
    Ana Bocanegra
    Laura Llorente
    Cristina Muñoz-Linares
    Ana Morales
    Eugenio Giménez
    Rebeca Iglesias
    Carmen Martínez-Chamorro
    Aránzazu Alonso
    Carmen Jiménez-Montes
    María J. Blanchard
    Oncology and Therapy, 2023, 11 : 83 - 96
  • [29] Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Roussou, Maria
    Eleutherakis-Papaiakovou, Evangelos
    Spiliopoulou, Vassiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios-Athanasios
    Gavriatopoulou, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [30] Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
    Alegre, Adrian
    Benzo, Gonzalo
    Alonso, Rafael
    Martinez-Lopez, Joaquin
    Jimenez-Ubieto, Ana
    Cuellar, Clara
    Askari, Elham
    Prieto, Elena
    Alaez, Concepcion
    Aguado, Beatriz
    Velasco, Alberto
    Krsnik, Isabel
    Bocanegra, Ana
    Llorente, Laura
    Munoz-Linares, Cristina
    Morales, Ana
    Gimenez, Eugenio
    Iglesias, Rebeca
    Martinez-Chamorro, Carmen
    Alonso, Aranzazu
    Jimenez-Montes, Carmen
    Blanchard, Maria J.
    ONCOLOGY AND THERAPY, 2023, 11 (01) : 83 - 96
12345